Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2023-04-19 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
拟续聘会计师事务所公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (auditor) for the company's 2023 annual audit. It details the auditor's background, independence, audit fees, and the board's approval process. It does not contain any financial statements or audit results, nor is it a full audit report or annual report. The document is relatively short (3086 characters) and serves as a formal announcement of the auditor appointment process, which is typically regulatory or corporate governance related. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement about auditor reappointment rather than the audit report itself or an annual report.
2023-04-19 Chinese
2022年度审计报告
Regulatory Filings
2023-04-19 Chinese
2022年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled '2022年度独立董事述职报告' which translates to '2022 Annual Independent Directors' Report'. It details the independent directors' attendance at board and shareholder meetings, their independent opinions on various board resolutions, their investigations into company operations, and their efforts to protect investors' rights. The document does not contain financial statements or detailed financial performance data. It is a report on the independent directors' duties and activities during the year, which is a form of management or board information rather than a full annual report or audit report. It is not a call transcript, earnings release, or any other category. Therefore, the best fitting category is Board/Management Information (MANG). The document length is 2312 characters, which is relatively short but contains substantive content about board activities, not just an announcement or certification, so it is not RPA or RNS.
2023-04-19 Chinese
2022年年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (334 characters) from Guangdong Yongshun Biopharmaceutical Co., Ltd. It states that the 2022 Annual Report and its summary were disclosed on April 20, 2023, on the official Beijing Stock Exchange information platform. The text explicitly mentions the report has been published and directs investors to review it. There is no actual financial data or detailed report content included, only a notification of the report's availability. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement, not the Annual Report itself.
2023-04-19 Chinese
2022年度非经营性资金占用及其他关联资金往来情况的专项审计说明
Regulatory Filings
2023-04-19 Chinese
第四届监事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on various agenda items including approval of the 2022 Supervisory Board Work Report, 2022 Annual Report, financial reports, budget, dividend distribution plan, and other governance-related reports. The document references other reports and announcements published separately on the Beijing Stock Exchange website, indicating this document itself is a formal meeting resolution announcement rather than the reports themselves. The content is focused on board/management decisions and approvals, not the full financial or operational reports. Therefore, the document fits best into the category of Board/Management Information (MANG). The document length is 3136 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report.
2023-04-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.